Innovent Biologics, Inc. (HKG:1801)
Hong Kong
· Delayed Price · Currency is HKD 85.90
+4.15 (5.08%)
Mar 10, 2026, 1:38 PM HKT
Innovent Biologics Employees
Innovent Biologics had 6,190 employees as of June 30, 2025. The number of employees increased by 531 or 9.38% since the number was reported on December 31, 2024.
Employees
6,190
Change
531
Growth
9.38%
Revenue / Employee
2.02M HKD
Profits / Employee
200.45K HKD
Market Cap
141.85B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| WuXi Biologics | 12,552 |
| Sino Biopharmaceutical | 23,056 |
| Akeso | 3,529 |
| Sichuan Kelun-Biotech Biopharmaceutical | 1,870 |
| BeOne Medicines AG | 11,000 |
| RemeGen | 3,070 |
| 3SBio | 6,268 |
| Shanghai Henlius Biotech | 3,537 |
Innovent Biologics News
- 9 days ago - Hong Kong-listed Chinese drug firms set to turn corner on rising sales, licensing deals - South China Morning Post
- 25 days ago - Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer - PRNewsWire
- 4 weeks ago - Hong Kong stocks extend bounce-back from tech turbulence as risk sentiment returns - South China Morning Post
- 4 weeks ago - Innovent Biologics Strikes Partnership Deal With Eli Lilly - WSJ
- 4 weeks ago - China's Innovent clinches new Lilly deal for immunology, cancer drug development - Reuters
- 4 weeks ago - Hong Kong stocks start week strong on sentiment stabilisation, Japan election - South China Morning Post
- 4 weeks ago - Innovent And Lilly Expand Collaboration To Advance Global Oncology & Immunology Drugs - Nasdaq
- 4 weeks ago - Innovent Biologics (IVBIY) Expands Partnership with Eli Lilly for Cancer Drug Development - GuruFocus